Paul Wright
Senior Director, API Development and Manufacturing, Kailera Therapeutics
Kailera: Advancing Next-Generation Therapies for Obesity
Company Description
Kailera was launched in October 2024 with an experienced leadership team and a strong investor syndicate who possess a track record of building successful companies. Kailera is advancing a broad and advanced pipeline, including peptides and small molecules, which have the ability to help a broad range of obesity patients, including those with the highest unmet medical need (BMI 35+). This talk will provide an overview of the company and its assets.
Bio
Dr. Wright is a seasoned CMC leader with a PhD in analytical chemistry from the University of Cincinnati. He has served in several CMC cross-functional technical and management leadership roles at Eli Lilly and MBX Biosciences prior to joining Kailera as the Senior Director of API Development and Manufacturing.